In the BioHarmony Drug Report Database
Zemdri (plazomicin) is a small molecule pharmaceutical. Plazomicin was first approved as Zemdri on 2018-06-25. It is used to treat escherichia coli infections, pyelonephritis, and urinary tract infections in the USA. Zemdri (plazomicin)’s patents are valid until 2031-06-02 (FDA).
Image (chem structure or protein)